Gapping down
In reaction to disappointing earnings/guidance:
In reaction to disappointing earnings/guidance:
- OPTT -6.6%
Other news:
- OPHT -81.8% (reports Phase 3 results for Fovista; No benefit observed upon addition of Fovista to monthly Lucentis regimen)
- ALXN -13.2% (names David Brennan as Interim CEO effective immediately; new CFO also named; update on audit investigation provided)
- PTI -8.8% (receives notice of termination from Biogen (BIIB) relating to their collaborative research, development, commercialization and license agreement)
- CNI -2.5% (cautious report from SIRF)
- OTEX -1.9% (launches an underwritten public offering of $500 mln of common shares )
- BIDU -1.1% (in sympathy with Shanghai down 2.5% overnight)
Analyst comments:
- GFI -1.4% (downgraded to Sector Perform at RBC Capital Mkts)
- MDXG -1.4% (initiated with a Sell at UBS)